(3rd November, 2014; Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, and U.S.-based CytoSorbents Corporation (OTCQB: CTSO) announced today that they have expanded the scope of their strategic partnership for CytoSorbents’ CytoSorb® cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS). SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.
[adsense:336x280:8701650588]